학술논문

Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy.
Document Type
Article
Source
Current Oncology. Jan2023, Vol. 30 Issue 1, p1146-1150. 5p. 1 Graph.
Subject
*DISEASE progression
*T cells
*HEMATOPOIESIS
*KARYOTYPES
*MEDICAL care costs
Language
ISSN
1198-0052
Abstract
We present the case of a 64-year-old man diagnosed with large B-cell lymphoma who relapsed twice after standard-of-care therapy. Due to persisting cytopenia, Next generation sequencing analysis was performed, revealing a small TP53-mutated clone. As a third-line therapy, the patient was treated with CAR-T cells, which resulted in complete remission. However, this treatment also led to the expansion of the TP53-mutated clone and therapy-related myelodysplasia with a complex aberrant karyotype. This case may serve as a paradigmatic example of clonal hematopoietic progression in a patient undergoing CAR-T cell therapy, especially in the context of a TP53-mutated clone. [ABSTRACT FROM AUTHOR]